CME LIVE OPEN ACCESS

Journal of Cancer Research

Review Article

ISSN: 2578-3726

Liposomal Nanocarriers from Concept to Clinical Applications

Ashutosh Sengar*

Assistant Professor, Dept. of Pharmaceutics, Smt. Vidyawati College of Pharmacy, Smt. Vidyawati Group of Institutions, Jhansi (U. P).

Corresponding Author: Ashutosh Sengar, Assistant Professor, Dept. of Pharmaceutics, Smt. Vidyawati College of Pharmacy, Smt. Vidyawati Group of Institutions, Jhansi (U. P).

Received: 2025 Mar 13 **Accepted:** 2025 Apr 01 **Published:** 2025 Apr 11

Abstract

Liposomal drug delivery systems have been used as an innovation tool in nanomedicine to show improved drug stability, release control, and targeted therapy. The review provided in this chapter reviews the evolutionary history of liposomes, constitutional structure, and classification. Mechanistic attributes of drug release, stealth liposomes, and functionalized carriers reflect innovations that deliver the best in therapeutic efficacy. Their use in cancer therapy, crossing the blood-brain barrier, infection, and gene therapy are a few examples of their utility in contemporary medicine. Liposomes are more biocompatible and provide controlled drug release compared to polymeric nanoparticles but are difficult for stability and large-scale production. Scanning and regulation are also obstacles to commercialization. But there is hope in the following positive trends: AI-aided liposomal design, hybrid nanocarriers, and theranostic use, which shall be the next-generation drug delivery systems. This review presents an overall impression of the development, challenge, and future trend of liposomes, which is engaged in the construction of precision medicine.

Keywords: Liposomal Drug Delivery, Nanomedicine, Targeted Therapy, Pegylation, Stimuli Responsive Liposomes

1. Introduction to Liposomal Drug Delivery Systems

Liposomal drug delivery has transformed the field of pharmacology through improved drug stability, bioavailability, and site-specific drug delivery. The nano-vesicles, first discovered in the 1960s, were initially employed in studies on membrane biology but eventually came into prominence in pharmaceutical research [1]. The advance was created in the 1990s when the FDA certified the first liposomal drug product to treat cancer, Doxil®. This advance led to swift progress and transformed liposomes into a complex nanocarrier for multiple therapeutic applications [2]. Liposomes are made up of a phospholipid bilayer that encapsulates an aqueous core and hence act as a good drug carrier. Liposomes are classified into small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs), and multilamellar vesicles (MLVs) based on structure [3]. Some modifications that are considered to be functional ones include PEGylation for prolonging circulation time and ligand-targeted liposomes for targeted drug delivery [4].

2. Mechanisms and Innovations in Liposomal Drug Carriers

2.1. Liposomal Drug Release and Stability Mechanisms

Release from liposomes is influenced by the lipid structure, pH sensitivity, and external stimuli. External stimuli like temperature or pH change lead to fast release, whereas passive diffusion allows for slow leakage of the drug. Balance in lipid composition and cholesterol content can facilitate stability by preventing premature leakage by the formation and integrity of membranes [5,6]. Circulation time of sterically stabilized liposomes is also enhanced due to minimal aggregation and degradation [7].

2.2. Stealth Liposomes and PEGylation

Stealth liposomes are designed to carry PEG at the surface for avoiding immune recognition and enhancing systemic circulation. PEGylation decreases opsonization, which avoids rapid MPS removal. PEGylation has contributed significantly to drug pharmacokinetics that are being encapsulated into liposomes by making them more appropriate for cancer treatment and other therapies for prolonged drug delivery [8]. Immune recognition is also reduced, which increases the drug accumulation in target sites and thus improves therapeutic effects [9].

2.3. Stimuli-Responsive Liposomes and Functionalization

Thanks to developments in liposomal technology, stimuli-responsive carriers that release medications in response to particular physiological situations have been developed. Drugs are released via pH-sensitive liposomes in acidic tumor settings and by temperature-sensitive liposomes at higher temperatures. Site-specific targeting is further improved by functionalization with ligands, antibodies, or peptides, which raises therapeutic efficacy while lowering systemic toxicity [10]. These developments maximize therapeutic potential by increasing medication delivery accuracy [11].

3. Clinical Applications and Targeting Strategies

3.1. Liposomes in Cancer Therapy and Tumor Targeting

Liposomal drug delivery stands as a crucial cancer therapy

advancement because it enables better drug distribution to tumor areas and decreases dangerous side effects to the entire body. Liposomes use enhanced permeability and retention (EPR) effect for passive targeting which enables them to accumulate in cancer tissues because of their poor-quality blood vessels. The therapeutic efficiency of liposomes improves when researchers integrate functional targeting components like antibodies or ligands to enhance the binding properties for cancer cells [12].

The FDA has approved two liposomal formulations which include Doxil® and Myocet® that maintain better drug retention in tumours while extending circulation durations. The use of liposomes in treatment has reduced cardiotoxic risks better than traditional chemotherapy thus becoming a preferred choice for oncological therapy [13]. Scientific study investigates liposomes with dual imaging and therapeutic properties for specific tumor treatment applications [14].

3.2. Drug Delivery Across the Blood-Brain Barrier

The blood-brain barrier (BBB) stands as a major hindrance for neurological disorder therapeutic delivery. The advanced nature of liposomes as therapeutic agents depends on their tandem use of receptor-mediated transcytosis and surface manipulations which enhances their penetration into the brain. Through their incorporation of transferrin or lactoferrin liposomes achieve superior brain-entry results which enhance their access to patients suffering from neurodegenerative diseases or glioblastoma [15]. A number of scientific studies prove PEGylated liposomes work well as drug delivery systems since they preserve drug stability and block immune system clearance. The brain entry of liposomes faces limitations because of serum protein consumption which requires better surface chemistry adjustments [16].

3.3. Liposomes in Infectious Diseases and Gene Therapy

The management of infectious diseases as well as gene therapy advancement needs enduring support from liposomal technology which extends beyond its applications in cancer treatment and neurology. The drug encapsulation process in liposomes converts antimicrobial agents into formulations which improve stability and bioavailability and enhance drug solubility against pathogenic resistance. Liposomal medications have served as therapeutic agents for treating tuberculosis and fungal infections and antiviral diseases according to [17]. The use of cationic liposomes enhances nucleic acid transfection efficiency whereas their degradation process is blocked during gene therapy. Research teams work to optimize Targeted liposomal gene delivery systems because they advance genetic disorder treatments and develop personalized medicine methods to enhance stability alongside unwanted side effect prevention [18].

4. Comparative Study of Liposomes and Other Nanocarriers

4.1. Liposomes vs Polymeric Nanoparticles

Liposomal and polymeric nanocarriers exist as top drug delivery systems due to their ability to provide specific advantages for pharmaceutical systems. Nanoparticles formed from liposomes achieve biocompatible properties and maintenance control through their bilayer phospholipid structure. The nanocarriers establish dual membrane replication which enables them to accomplish maximum drug loading capabilities and precise delivery functions. Polymeric nanoparticles have superior longevity compared to both polymeric nanoparticles and other systems yet maintain better stability than these competitors [19]. Particles that combine chitosan with PLGA maintain better technical stability with agile pharmaceutical drug release mechanisms. The controlled drug delivery systems in drug carriers deliver enhanced performance compared to liposomes since they decrease the frequency of medication requirements. However, concerns over biocompatibility and potential toxicity limit their widespread use in clinical applications [20].

4.2. Multifunctional Nanocarriers and Imaging Capabilities

New technological progress has enabled researchers to create nanocarriers which combine therapeutic components with diagnostic (theranostic) functions. The combination of lipospheres with various diagnostic agents such as contrast agents and fluorescent dyes and magnetic nanoparticles enables real-time tracking as well as drug delivery. The dual capability of these nanocarriers improves their ability to deliver precise treatment in cancer therapy [21].

The use of smart liposomal systems introduces self-triggered drug release elements through pH or enzyme activation which enhances drug delivery effectiveness. Precision medicine will benefit tremendously from the integrated approach of imaging with targeted therapy although researchers need to optimize both targeting precision and off-target side effects reduction [22].

5. Challenges and Future Prospects

5.1. Stability, Scalability, and Regulatory Aspects

Industrial pharmaceutical distribution of liposomal drugs encounters two primary obstacles related to formulation stabilization methods and achieving wider manufacturing facility capabilities and medical approval authorities. Liposomes break down prematurely and form molecular aggregates with leakages when stored because of their environments which reduces their operational period. Research on liposomal stability enhancement focuses on lipid optimization and drug stabilizer application studies [23]. The thin-film hydration extrusion manufacturing method for liposomes fails to create homogenous production batches thereby hindering large-scale growth. The solution for manufacturing defects lies in system production through microfluidics using large-scale production techniques. Regulatory agency testing requirements for safety and efficacy slow down medical drug delivery in the clinical phase. The market approval process for regenerative medicine depends on standardized production approaches and sophisticated characterization techniques per the research findings published in 2018 [24].

5.2. Future Trends in Liposomal Research

Liposomal research is moving toward precision medicine

with focus on individualized therapy and improved targeting modalities. Stimuli-responsive drug-releasing functionalized liposomes with enzyme- or light-inducible release mechanisms are being developed to allow for treatment specificity [25]. Machine learning and artificial intelligence (AI) are also being explored for use in liposomal formulation. Optimal lipid composition can be rationally designed, and drug release profiles can be predicted using artificial intelligence algorithms for the design of next-generation nanocarriers [26]. Multicomponent hybrid liposomes with greater than one nanomaterial, e.g., polymers or inorganic nanoparticles, also show promise for control of drug delivery and control of theranostic function [27].

6. Conclusion

The liposomal drug delivery system has created revolution in nanomedicine in terms of improving stability, bioavailability, and targeted delivery of drugs. Initially developed over time, the liposomes have established themselves in high potential toward clinical practice. Circulation time and efficient targeting primarily caused by PEGylation and stimulus response have furthermore supported successful targeted cancer treatment and effective drug delivery across the blood-brain barrier. Liposomes have also contributed to the treatment of infectious diseases and gene therapy, along with a bright prospect for nanomedicine in terms of flexibility.

It enumerates the merits of liposomes compared to other nanocarriers in terms of biocompatibility and control of drug release. Some other significant challenges include stability, scalability, and regulatory hurdles prior to a broad clinical impact. Future trends include AI-aided optimization, hybrid nanocarriers, and theranostic liposomal systems for a promising future roadmap of research and application. In summary, liposomal drug delivery continues to improve and bridge the gap between experimental and clinical nanomedicine. Much has already been achieved, but additional technological advances and research are needed in order to overcome current limitations and fully capitalize on the therapeutic potential of liposomal formulations for precision medicine.

References

1. Sengar, A. (2025). Historical Evolution and Modern Advances in Vesicular Nanocarriers.
2. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. *Advanced drug delivery reviews, 65*(1), 36-48.
3. Sengar, A. (2025). Innovations and mechanisms in liposomal drug delivery: A comprehensive introduction. *Journal of Emergency Medicine Open Access (J Emerg Med OA), 3*(1), 01-05.
4. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., ... & Nejati-Koshki, K. (2013). Liposome: classification, preparation, and applications. *Nanoscale research letters, 8*, 1-9.
5. Lian, T., & Ho, R. J. (2001). Trends and developments in liposome drug delivery systems. *Journal of pharmaceutical sciences, 90*(6), 667-680.
6. Barenholz, Y. C. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. *Journal of controlled release, 160*(2), 117-134.
7. Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. *Pharmacological reviews, 51*(4), 691-743.
8. Laura Immordino, M., Dosio, F., & Cattel, L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. *International journal of nanomedicine, 1*(3), 297-315.
9. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. *Nature reviews Drug discovery, 4*(2), 145-160.
10. Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. *Nature materials, 12*(11), 991-1003.
11. Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome assisted drug delivery. *Frontiers in pharmacology, 6*, 286.
12. Deshpande, P. P., Biswas, S., & Torchilin, V. P. (2013). Current trends in the use of liposomes for tumor targeting. *Nanomedicine, 8*(9), 1509-1528.
13. Malam, Y., Loizidou, M., & Seifalian, A. M. (2009). Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. *Trends in pharmacological sciences, 30*(11), 592-599.
14. Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012). Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. *Journal of controlled release, 161*(2), 175-187.
15. Chen, Y., & Liu, L. (2012). Modern methods for delivery of drugs across the blood–brain barrier. *Advanced drug delivery reviews, 64*(7), 640-665.
16. Johnstone, S. A., Masin, D., Mayer, L., & Bally, M. B. (2001). Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly (ethylene glycol) liposomes by mouse macrophages. Biochimica et Biophysica Acta (BBA)-*Biomembranes, 1513*(1), 25-37.
17. Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017). Liposomal formulations in clinical use: an updated review. *Pharmaceutics, 9*(2), 12.
18. Sengar, A. (2025). Advanced Targeting Strategies and Applications of Liposomal Drug Delivery Systems.
19. Sengar, A. (2025). The Interplay of Drug Delivery Systems: A Comparative Study of Nanocarriers and Vesicular Formulations.
20. Beltrán-Gracia, E., López-Camacho, A., Higuera-Ciapara, I., Velázquez-Fernández, J. B., & Vallejo-Cardona, A. A. (2019). Nanomedicine review: Clinical developments in liposomal applications. *Cancer Nanotechnology, 10*(1), 1-40.
21. Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012). Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. *Science, 338*(6109), 903-910.
22. Andresen, T. L., Jensen, S. S., & Jørgensen, K. (2005). Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. *Progress in lipid research, 44*(1), 68-97.
23. Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015). New

developments in liposomal drug delivery. *Chemical Reviews, 115*(19), 10938-10966.
24. Mishra, H., Chauhan, V., Kumar, K., & Teotia, D. (2018). A comprehensive review on Liposomes: a novel drug delivery system. *Journal of Drug Delivery and Therapeutics, 8*(6), 400-404.
25. SENGAR, A. (2025). Next-Generation Liposomal Drug Delivery Systems: Core Principles, Innovations, and Targeting Strategies.
26. Cullis, P. T., & De Kruijff, B. (1979). Lipid polymorphism and the functional roles of lipids in biological membranes. *Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes, 559*(4), 399-420.
27. Gao, W., Hu, C. M. J., Fang, R. H., & Zhang, L. (2013). Liposome-like nanostructures for drug delivery. *Journal of Materials Chemistry B, 1*(48), 6569-6585.